Palivizumab Utilization and Compliance: Trends in Respiratory Syncytial Virus Prophylaxis in Florida

Journal of Pediatrics

Volumn 156, Issue 6, 2010, Pages

  Hampp, Christian ^a   Saidi, Arwa S ^b   Winterstein, Almut G ^a,c  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CHILD; CHRONIC LUNG DISEASE; CONGENITAL HEART DISEASE; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG INDICATION; DRUG UTILIZATION; FEMALE; GESTATIONAL AGE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PREMATURITY; PRESCHOOL CHILD; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SEASONAL VARIATION; SEVERE COMBINED IMMUNODEFICIENCY; TREND STUDY; UNITED STATES;

EID: 77952287646     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2009.12.016     Document Type: Article

References (20)

1. Shay D.K., Holman R.C., Newman R.D., Liu L.L., Stout J.W., and Anderson L.J. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 282 (1999) 1440-1446
2. Hall C.B., Weinberg G.A., Iwane M.K., Blumkin A.K., Edwards K.M., Staat M.A., et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 360 (2009) 588-598
3. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102 3 Pt 1 (1998) 531-537
4. Feltes T.F., Cabalka A.K., Meissner H.C., Piazza F.M., Carlin D.A., Top Jr. F.H., et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 143 (2003) 532-540
5. Drug Topics Red Book. Pharmacy's Fundamental Reference. Montvale, NJ: Thomson PDR (December 2006)
6. Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 112 6 Pt 1 (2003) 1442-1446
7. Brief report. respiratory syncytial virus activity-United States, July 2006-November 2007. MMWR 56 (2007) 1263-1265
8. Bauman J., Eggleston M., Oquist N., and Malinoski F. Respiratory syncytial virus: seasonal data for regions of Florida and implications for palivizumab. South Med J 100 (2007) 669-676
9. http://www.doh.state.fl.us/Disease_ctrl/epi/RSV/rsv_trends.htm. Accessed 07/09/2009.
10. http://www.cdc.gov/surveillance/nrevss/rsv/default.html. Accessed 02/23/2009.
11. Committee on Infectious Diseases and Committee on Fetus and Newborn. Prevention of Respiratory Syncytial Virus Infections: Indications for the Use of Palivizumab and Update on the Use of RSV-IGIV. Pediatrics 102 (1998) 1211-1216
12. Mansbach J., Kunz S., Acholonu U., Clark S., and Camargo Jr. C.A. Evaluation of compliance with palivizumab recommendations in a multicenter study of young children presenting to the emergency department with bronchiolitis. Pediatr Emerg Care 23 (2007) 362-367
13. Moynihan J.A., Kim T.Y., Young T., and Checchia P.A. Rate of palivizumab administration in accordance with current recommendations among hospitalized children. J Pediatr Health Care 18 (2004) 224-227
14. Pignotti M.S., Catarzi S., and Donzelli G.A. 4-year survey on palivizumab respiratory syncytial virus (RSV)-prophylaxis: how can compliance be improved?. J Matern Fetal Neonatal Med 19 (2006) 221-224
15. Oh P.I., Lanctjt K.L., Yoon A., Lee D.S., Paes B.A., Simmons B.S., et al. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes. Pediatr Infect Dis J 21 (2002) 512-518
16. Giusti R. North American synagis prophylaxis survey. Pediatr Pulmonol 44 (2009) 96-98
17. Respiratory Syncytial Virus. Red Book 2009;1:560-569.
18. Bellavance M., Rohlicek C.V., Bigras J.L., Cote J.M., Paquet M., Lebel M.H., et al. Palivizumab use among children with congenital heart disease in Quebec: impact of Canadian guidelines on clinical practice. Paediatr Child Health 11 (2006) 19-23
19. Hampp C., Winterstein A.G., and Saidi A. Role of Age in Respiratory Syncytial Virus Infection Risk: Recommendations for Palivizumab Utilization, presented at 24th International Conference on Pharmacoepidemiology and Therapeutic Risk Management. Pharmacoepidemiol Drug Safety 17 (2008) 186
20. Jacobson Vann J., Feaganes J., and Wegner S. Reliability of medicaid claims versus medical record data: in a cost analysis of palivizumab. Pharmacoeconomics 25 (2007) 793-800